The Cook Zilver PTX Drug-eluting Stent Versus Bypass Surgery for the Treatment of Femoropopliteal TASC C&D Lesions (ZILVERPASS).
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 09 Mar 2018
Price : $35 *
At a glance
- Drugs Paclitaxel (Primary)
- Indications Peripheral artery restenosis; Peripheral vascular disorders
- Focus Therapeutic Use
- Acronyms ZILVERPASS
- 05 Mar 2018 Planned End Date changed from 1 Sep 2017 to 1 Dec 2019.
- 05 Mar 2018 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018.
- 05 Mar 2018 Status changed from recruiting to active, no longer recruiting.